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Background: There have been few reports regarding quetiapine-associated hematological effects other than
white-blood-cell alteration. We present the first reported Han-Chinese case that developed leucopenia and
thrombocytopenia after taking quetiapine.
Case presentation: We present a case of a person with a bipolar I disorder who experienced leucopenia and
thrombocytopenia after taking 400 mg/day of quetiapine and 1000 mg/day of valproic acid for three and one-half
months.
The hematological toxicity abated upon the discontinuation of both drugs. However, due to the intolerable side
effects of the replaced antipsychotic (haloperidol), and according to the patient’s preference, we prescribed
quetiapine and valproic acid again. There was a recurrence of leucopenia and a decreased platelet count by the
sixth day. The adverse effects disappeared soon after we discontinued quetiapine, while keeping valproic acid
treatment.
Conclusion: Quetiapine-associated leucopenia and thrombocytopenia seems reversible but possibly fatal.
Therefore, clinical practitioners should be aware of this adverse reaction.
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Quetiapine is a commonly-prescribed atypical antipsychotic
drug used worldwide for schizophrenia and mood disor-
ders. It is a dibenzothiazepine derivative related to clozapine
in chemical structure and pharmacological profile [1,2].
Several cases of quetiapine-associated hematologic side
effects have been reported. Leucopenia (a white blood
cell count below 4.0 × 103/μL) develops in approximately
one percent of the subjects treated with quetiapine, and it
is resolved upon discontinuation [1]. In addition, some
reports indicate neutropenia (an absolute neutrophil
count below 1.5 × 103/μL) and agranulocytosis (an abso-
lute neutrophil count below 500/μL) may emerge when
using quetiapine [1].
There have been fewer case reports addressing
quetiapine-associated hematological effect of combined
alteration of white-blood-cells and platelets. We could
find only two reports in previous literature reporting* Correspondence: wenyin19@gmail.com
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(a platelet count below 150 × 103/μL) [2,3]. We will present
a case study of a person who developed leucopenia and
thrombocytopenia after taking quetiapine.
Case presentation
Mr. A, a twenty-three-year-old man, was diagnosed as
having a bipolar I disorder at the age of nineteen due to
the manifestations of manic symptoms with psychotic
features. He had been admitted six times in various hos-
pitals for the management of recurrent manic episodes.
He had successively taken lithium, valproic acid, and
carbamazepine, though with poor drug compliance after
his hospital discharge. He did not have a history of sys-
temic or hematologic diseases.
After taking 400 mg/day of quetiapine and 1000 mg/day
of valproic acid for four weeks, with no other psychotropic
agents, he was transferred to our rehabilitation ward for
occupational training. On the first day of admission, rou-
tine blood tests revealed a white blood cell (WBC) count
of 4.37 × 103/μL, an absolute neutrophil count (ANC) of
1.56 × 103/μL, a red blood cell (RBC) count of 4.63 × 106/is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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count of 149 × 103/μL.
Unfortunately, after a total of three and one-half
months with the above medications, he developed a
sudden onset of fever and upper respiratory tract infec-
tion (Day 0). Two days later (Day 2), his leucopenia,
neutropenia, and thrombocytopenia counts were noted
as follows: WBC 1.99 × 103/μL, ANC 860 /μL, platelet
81 × 103/μL, while his RBC and Hb remained in the nor-
mal ranges. We stopped using valproic acid on Day 2
and closely monitored the clinical conditions. However,
the fever persisted; and the laboratory data showed
agranulocytosis with thrombocytopenia (WBC 1.63 ×
103/μL; ANC 500/μL; platelet 76 × 103/μL) on Day 4.
Therefore, we immediately discontinued quetiapine. His
clinical condition stabilized on Day 6, with the lab data
showing the following: WBC 2.84 × 103/uL, ANC 1,107/
μL, and platelet 91 × 103/μL. On day 8, there was an ob-
vious improvement of the hematological profile (WBC
7.92 × 103/μL; ANC 5,726/μL; platelet 171 × 103/μL).
On Day 9, due to an acute worsening of manic and
psychotic symptoms, we prescribed 10 mg/day of haloperi-
dol. However, we noticed severe and intolerable extra-
pyramidal side effects. Considering the patient’s preference,
200 mg/day of quetiapine and 500 mg/day of valproic acid
were administered on Day 18 and were titrated up to
400 mg/day and 1000 mg/day, respectively on Day 20. With
a cautious follow-up of the hematological data, we noted
the following: leucopenia (WBC 3.12 × 103/μL), a decreased
neutrophil count (ANC 1,719/μL), and thrombocytopenia
(136 × 103/μL) again on Day 24 without clinical symptoms.
On Day 26, we discontinued quetiapine and shifted the
medication to 4 mg/day of risperidone, while maintaining
the valproic acid treatment. On Day 30, we observed nor-
mal white-blood-cell and neutrophil count (WBC 7.22 ×
103/μL, ANC 5,595/μL), and a platelet count closer to nor-
mal range (platelet 149 × 103/μL). The patient has not been
administered quetiapine since then, and the hematological
follow-up examinations have all revealed normal results
thereafter.
We have presented a case of a man with a bipolar I
disorder who developed leucopenia, neutropenia, and
thrombocytopenia after being administered quetiapine
and valproic acid. The hematological abnormalities were
resolved upon discontinuation of both drugs but re-
emerged following the reuse of them. However, the ab-
normalities abated again after we stopped quetiapine
but continued using valproic acid. The temporal rela-
tionship between drug exposure and laboratory data
suggests direct quetiapine toxicity. In our case, the
Naranjo adverse drug-reaction probability scale was
seven, which suggested a probable causality.
We could find only two reports in previous litera-
ture reporting quetiapine-associated leucopenia andthrombocytopenia [2,3]. Both of them were published
case report, in which the adverse reactions were de-
scribed in detail. They reported hematological toxicity
after 600 mg/day of quetiapine were administered for
five weeks [2] and 400 mg/day for four years [3].
These adverse effects, similar to our patient’s, were all
resolved upon discontinuation of quetiapine and the
investigations for other etiological causes all showed
no remarkable findings. However, neither of them
stated the reuse of quetiapine as our case. There has been
only one case report describing quetiapine-associated pan-
cytopenia (50 mg/day for 3 weeks) [4]. These reports
showed that the duration of quetiapine use before the on-
set of hematological adverse effects might be between sev-
eral weeks to several years. As in our case, the duration
was approximately three and one-half months, which was
compatible with previous reports.
However, we cannot completely exclude the contribut-
ing effect of valproic acid. Two case reports also showed
that neutropenia might be induced by a combined use of
quetiapine and valproic acid [5,6]. It has been suggested
that the co-medication of valproic acid would increase the
plasma level of quetiapine by seventy-seven percent be-
cause of the inhibiting effect on cytochrome P450 3A4 [6].
Nevertheless, we believe quetiapine played a crucial role
in the hematological toxicity of our case since we observed
a rapid restoration after the cessation of its use. Similarly,
another case report also showed that thrombocytopenia
occurred after co-administration of quetiapine and val-
proic acid but still persisted despite valproic acid discon-
tinuation, suggesting a unique propensity of quetiapine to
trigger hematological toxicity [7].
The mechanisms underlying the toxicity remained un-
clear. Given a resemblance of the chemical structure and
similar pharmacological profile, it has been speculated
that quetiapine could cause bone-marrow depression
similar to clozapine [2]. Both drugs are characterized by
high 5HT2-relative-to-DA2 receptor affinity and virtually
no affinity for muscarinic receptors [2]. Olanzapine is an-
other antipsychotic drug which is related to quetiapine
and clozapine in chemical structure and pharmacological
profile. The rarer adverse effect of the combination of
leucopenia and thrombocytopenia has also been reported
in patients administered olanzapine [8]. Other mecha-
nisms, including immune-mediated toxicity, induction of
free radicals, and the formation of an intermediate
nitrenium ion, have also been proposed to explain the
phenomenon [3].
According to our case report, we do not have adequate
information to conclude whether this phenomenon was
dose-related or idiosyncratic. A previous case report stated
that quetiapine-induced leucopenia might be a possible
dose-dependent phenomenon [9]. According to the ex-
perience of clozapine, both dose-dependent toxicity and
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nisms of clozapine-induced blood dyscrasia, which might
show some similarity to quetiapine [10]. Further studies
are needed to investigate this phenomenon.
We presented the first case in Han-Chinese of quetiapine-
associated leucopenia and thrombocytopenia. Another
unique aspect of our case is the reuse of quetiapine
in the treatment course, which hasn’t been mentioned
in previous case reports. Nevertheless, the contributing
effects from the co-administered valproic acid cannot
be neglected. We hope our case report can help in accu-
mulating evidence and enhance further investigation to
find out clinical or biological factors related to this side
effect.
Conclusion
Quetiapine-associated leucopenia and thrombocytopenia
seem reversible but possibly fatal. Although it has not
been a clinical routine yet for a regular check-up of the
complete blood cell count in patients administered quetia-
pine, clinical practitioners should be aware of this adverse
reaction.
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